



## **Resinco Capital Partners Makes First Investment in Cannabis Pharma Sector**

**October 19th, 2018 - Vancouver, BC – Resinco Capital Partners Inc. (CSE:RIN)** (the “Company” or “Resinco”) announces that it has made an investment in Toronto, Ontario and Palo Alto, California based Cannabis Pharma company, Katexco Pharmaceuticals Corp.

The Company has now made its first investment in the Cannabis Pharma Sector with its investment in Katexco Pharmaceuticals. Katexco is led by a world class team of scientists that come from Stanford University in California. Resinco is excited to pursue further investments in the Cannabis Pharma Sector in the near future.

Prof. Lawrence Steinman, Chairman and Co-Founder of Katexco said, “We are extremely pleased to welcome Resinco Capital Partners as investors in Katexco.”

Alexander Somjen, President and CEO of Resinco said, “After announcing our decision to pursue investment opportunities in the growing Cannabis Pharma sector, Katexco made sense as our first Cannabis Pharma investment. With their world class team, Katexco is working on life changing treatments.”

### About Resinco Capital Partners

Resinco Capital Partners is a global investment company which specializes in providing early stage financing to private and public companies focused on the growing Cannabis Pharma Sector. The Company engages in new, early stage investment opportunities in previously underdeveloped life sciences and biotech companies which a specific focus on Cannabis Pharma, obtaining positions in early stage investment opportunities that adequately reflect the risk profile.

Website:

[www.resincocp.com](http://www.resincocp.com)

### About Katexco Pharmaceuticals Corp

Katexco Pharmaceuticals is a medical cannabis company developing innovative, orally available therapies harnessing endocannabinoid and nicotine receptors to treat inflammatory diseases. Formed by Dr. Jonathan Rothbard and Professor Lawrence Steinman, the Company is developing the world’s first drug to exploit a key receptor on immune cells in the brain with the ability to treat inflammatory diseases.

Website:

<https://katexcopharma.com/>  
Medical Cannabis Market Opportunity

The Medical Marijuana industry is rapidly growing. Currently the market is valued at \$14.3B USD. It is estimated to reach a market value of \$74.3B USD by 2027 at a projected CAGR of 17.9% from 2017 to 2027. Already over 1.2 million people use Medical Marijuana for medical problems.

Growth for its use is underpinned by numerous factors such as legislation permitting its use for medicinal benefits. Increasing research in the medical field has shown marijuana's benefits in suppressing vomiting and nausea, pain relief, whilst also generating a growing number therapeutic applications for inflammation, HIV/AIDS, cancer, multiple sclerosis, epilepsy, Huntington's disease and Parkinson's disease.

On behalf of the Board of Directors

**RESINCO CAPITAL PARTNERS INC.:**

Mr. Alexander Somjen, CEO

For more information, please contact  
Theo van der Linde- 604.336.3196

RESINCO CAPITAL PARTNERS  
Trading Symbol – CSE: RIN

Suite 810 – 789 West Pender Street  
Vancouver, BC V6C 1H2

T. 604.687.2038  
F. 604-687-3141

*Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.*

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on [www.sedar.com](http://www.sedar.com)